Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17454374 | 0.90 | ROCK2 (0.49) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL17437875 | 0.87 | ROCK2 (0.51) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL17452628 | 0.85 | ROCK2 (0.48) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL20654123 | 0.83 | ROCK2 (0.49) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL19902397 | 0.82 | PDE2A (0.39) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL20646991 | 0.82 | ROCK2 (0.45) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL20647024 | 0.82 | ROCK2 (0.40) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL20646745 | 0.81 | ROCK2 (0.40) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL24247778 | 0.80 | ROCK2 (0.46) | ROCK2PDE2APDE3APDE10A | |
| SCHEMBL24247786 | 0.80 | NR1I2 (0.39) | ROCK2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PDE2A 60/4885PDE3A 22/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | ROCK2 5/4885PDE2A 60/4885PDE3A 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.